Drug intelligence / Profile preview

PGSXC-L1C

Development stage: Unknown
Lead developer: PrimeGen Biotech
Modality: Stem Cell Therapies → Cell Therapies

Overview

PGSXC-L1C is an investigational stem cell therapy developed by PrimeGen Biotech for the treatment of chronic liver disease. The candidate is part of PrimeGen's portfolio of pluripotent stem cell-based treatments, which utilize germ cell-derived pluripotent stem cells (gPSCs) to promote tissue regeneration. According to the company's 2021 pipeline, PGSXC-L1C was in Phase 2 development for liver indications. The therapy is designed to address the underlying pathology of chronic liver conditions by potentially restoring liver function through the differentiation of stem cells into functional hepatocytes or by providing paracrine support to existing liver tissue to stimulate endogenous repair mechanisms.

Beyond the preview

Go deeper on PGSXC-L1C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PGSXC-L1C.

Explore the full profile